Confezione da 10 flaconi6 disponibiliRisparmia il 19%Retatrutide 50 mg
Peptide di ricerca triagonista GLP-1 / GIP / glucagone
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Solo per uso di ricerca. Questo composto è venduto strettamente per ricerca in vitro e scopi di laboratorio e non è destinato al consumo umano né a uso terapeutico. Acquistando, confermi di essere un ricercatore qualificato e accetti il nostro disclaimer completo.
Solo 6 confezioni rimaste
Peptide di ricerca agonista a triplo recettore, studiato per gli effetti combinati sulle vie di segnalazione di GLP-1, GIP e glucagone in applicazioni di ricerca metabolica.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Meccanismo
Studiato per l’agonismo simultaneo dei recettori di GLP-1, GIP e glucagone. Ricerca associata a marker di tasso metabolico, sazietà e dispendio energetico nelle popolazioni di studio.
Verificato in HPLC rispetto a una specifica di purezza ≥99 %. Testato in modo indipendente da laboratori terzi accreditati.
Retatrutide — domande frequenti
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Guide relative a Retatrutide
I ricercatori esplorano anche
Confezione da 10 flaconiRisparmia il 22%MOTS-c
Polvere liofilizzata10 mg · 2 strengths
Peptide metabolico di origine mitocondriale
In 2 combinazioni
Confezione da 10 flaconiRisparmia il 16%5-Amino-1MQ
Polvere liofilizzata50 mg · 3 strengths
Composto di ricerca inibitore di NNMT
Confezione da 10 flaconiRisparmia il 15%L-Carnitine
Sterile solution10 ml × 600 mg/ml
Trasportatore mitocondriale di acidi grassi
In 1 combinazione